Objective To study the relationship between serum zinc level and left ventricular diastolic dysfunction (LVDD) in patients with maintenance hemodialysis (MHD), and to explore the feasibility of serum zinc for early prediction of LVDD in MHD patients. Methods This was a single centered and cross-sectional study. A total of 96 MHD patients in the Blood Purification Center of Lianyungang First People's Hospital from Jun 2018 to Dec 2020 were recruited as the research objects. Serum zinc level was measured by flame atomic absorption spectrometry. According to the results of echocardiography, the patients were divided into LVDD group (n=52) and non-LVDD group (n=44). The clinical data, laboratory indexes and echocardiographic parameters were compared between LVDD group and non-LVDD group. The relationship between serum zinc level and other indexes in MHD patients was analyzed by Pearson and Spearman correlation methods. The factors affecting LVDD in MHD patients were analyzed by multivariate logistic regression. The diagnostic value of serum zinc for LVDD in MHD patients was analyzed by ROC. Results Serum zinc level in LVDD group was (90.15±10.44) μg/dl, lower than that in non-LVDD group (107.42±11.57) μg/dl, and the difference was statistically significant (t=7.618, P<0.001). Correlation analyses showed that serum zinc level in MHD patients was positively correlated with hemoglobin (r=0.263, P=0.017), and negatively correlated with E/E' (r=-0.447, P<0.001) and left atrial diameter (LAD) (r=-0.243, P=0.028). ROC curve showed that the area under curve (AUC) of serum zinc level in predicting LVDD in MHD patients was 0.817 (95% CI: 0.728~0.892, P=0.015), the predicted cutoff value was 95.85 μg/dL, the sensitivity was 78.44%, and the specificity was 76.02%. Multivariate logistic regression showed that lower serum zinc level was an independent risk factor for LVDD in MHD patients (OR=2.014, 95% CI: 1.414~7.015, P=0.005). Conclusion Lower serum zinc level is an independent risk factor for LVDD in MHD patients. Serum zinc may be an effective serological marker for predicting LVDD in MHD patients.
LIU Hui-Ru
,
ZHOU Yuan-Yuan
,
QIAO Juan
,
SHI Jun-Jun
. Lower serum zinc level was independently associated with left ventricular diastolic dysfunction in maintenance hemodialysis patients[J]. Chinese Journal of Blood Purification, 2023
, 22(02)
: 123
-127
.
DOI: 10.3969/j.issn.1671-4091.2023.02.010
[1]Hiyamuta H, Yamada S, Taniguchi M, et al. Causes of death in patients undergoing maintenance hemodialysis in Japan: 10-year outcomes of the Q-Cohort Study[J]. Clin Exp Nephrol, 2021, 25(10):1121-1130.
[2]Liu SX, Wu QJ, Zhang S, et al. Serum galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: A prospective cohort study[J]. BMC Nephrol, 2022, 23(1):5-14.
[3]Bramania PK, Ruggajo PJ, Furia FF. Prevalence and predictors of heart failure among patients on maintenance hemodialysis therapy at Muhimbili National Hospital in Tanzania: A cross-sectional study[J]. Egypt Heart J, 2021, 73(1):97-105.
[4]Gkirdis I, Naka KK, Lakkas L, et al. Coronary microcirculation and left ventricular diastolic function: comparison between patients on hemodialysis and peritoneal dialysis[J]. J Echocardiogr, 2020, 19(2):103-112.
[5]Sharifov O F, Schiros CG, Aban I, et al. Diagnostic accuracy of tissue doppler index E/e' for evaluating left ventricular filling pressure and diastolic dysfunction/heart failure with preserved ejection fraction: A systematic review and meta-analysis[J]. J Am Heart Assoc, 2016, 5(1):e002530.
[6]Gonalves AF, Polegato BF, Fernandes AA, et al. Zinc supplementation attenuates cardiac remodeling after experimental myocardial infarction[J]. Cell Physiol Biochem, 2018, 50(1):353-362.
[7]Yu XF, Huang L, Zhao JY, et al. The relationship between serum Zinc level and heart failure: A meta-analysis[J]. Biomed Res Int, 2018, 2018:2739014.
[8]于红燕, 杨海平, 耿文彦, 等. 慢性肾脏病患者左心室舒张期功能障碍的影响因素分析[J]. 临床荟萃, 2018, 33(11):974-977.
[9]孙琳琳, 朱鼎玉, 陈富华, 等. 血清超敏肌钙蛋白T与维持性血液透析患者左室舒张功能障碍的关系[J]. 中国中西医结合肾病杂志, 2019, 20(2):113-116.
[10]Bramania PK, Ruggajo PJ, Furia FF. Prevalence and predictors of heart failure among patients on maintenance hemodialysis therapy at Muhimbili National Hospital in Tanzania: a cross-sectional study[J]. Egypt Heart J, 2021, 73(1)97-105.
[11]吴敏, 侯毅, 李广义, 等. 影响维持性血液透析患者左心室舒张功能不全的多因素分析[J]. 中国血液净化, 2020, 19(5):298-300.
[12]Papamichail N, Bechlioulis A, Lakkas L, et al. Impaired coronary microcirculation is associated with left ventricular diastolic dysfunction in end-stage chronic kidney disease patients[J]. Echocardiography, 2020, 37(4):536-545.
[13]耿瑜, 李小明. 慢性心力衰竭患者血清锌水平与患者预后的关系[J]. 心脏杂志, 2019, 31(1):42-45.
[14]Liu Y, Zheng YY, Wang LT, et al. Lower levels of blood zinc associated with intradialytic hypertension in maintenance hemodialysis patients[J]. Biol Trace Elem Res, 2021, 199(7):2514-2522.
[15]Huang JC, Huang YC, Wu PY, et al. Association between reduced serum Zinc and diastolic dysfunction in maintenance hemodialysis patients[J]. Nutrients, 2021, 13(6):2077-2085.
[16]Kim W, Klarmann DK, Keller JR. Gfi-1 regulates the erythroid transcription factor network through Id2 repression in murine hematopoietic progenitor cells[J]. Blood, 2014, 124(10):1586-1596.
[17]Kokubo Y, Yokoyama Y, Kotemori A, et al. Seasonal changes in body iron status including erythropoiesis and hemolysis and dietary intakes among Japanese collegiate elite female rhythmic gymnasts[J]. J Phys Fit Sports Med, 2020, 9(4):149-156.
[18]杨艳华, 黄姣红, 安芳, 等. 贫血对慢性心力衰竭住院患者预后影响的回顾性分析[J]. 中华灾害救援医学, 2020, 8(12):664-667.
[19]Gonalves A, Polegato B, AnaAngélica Fernandes, et al. Zinc supplementation attenuates cardiac remodeling after experimental myocardial infarction[J]. Cell Physiol Biochem, 2018, 50(1):353-362.
[20]Jeejeebhoy F, Keith M, Freeman M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction[J]. Am Heart J, 2002, 143( 6):1092-1100.
[21]Khazdouz M, Djalalinia S, Zadeh SS, et al. Effects of zinc supplementation on cardiometabolic risk factors: A systematic review and meta-analysis of randomized controlled trials[J]. Biol Trace Elem Res, 2020, 195(2):373-398.
[22]Pompano LM, Boy E. Effects of dose and duration of zinc interventions on risk factors for type 2 diabetes and cardiovascular disease: A systematic review and meta-analysis[J]. Adv Nutr, 2021, 12(1):141-160.
[23]Efeovbokhan N, Bhattacharya SK, Ahokas RA, et al. Zinc and the prooxidant heart failure phenotype[J]. J Cardiovasc Pharmacol, 2014, 64(4):393-400.
